Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY)
Rhea-AI Filing Summary
Alnylam Pharmaceuticals Inc: Amendment No. 10 to a Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned of Alnylam common stock and 0% ownership as disclosed in the form. The filing includes a statement that Vanguard reorganized certain subsidiaries on January 12, 2026, and those entities will report separately following SEC Release No. 34-39538.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal realignment.
The filing states 0 shares beneficially owned and 0% of the class, indicating Vanguard does not hold reportable beneficial ownership in Alnylam via the reporting entity named here as of the amended filing.
The disclosure notes an internal realignment effective January 12, 2026, with subsidiaries to report separately under SEC Release No. 34-39538; subsequent filings by those subsidiaries may show separate positions.
FAQ
What does Vanguard report in the Schedule 13G/A for ALNY?
Does this Schedule 13G/A mean Vanguard has no connection to ALNY holdings?
What is the significance of the January 12, 2026 realignment mentioned?
Who signed the amended Schedule 13G/A for ALNY and when?
Will future filings show Vanguard ownership in ALNY after this amendment?